



S3 Fig. Kaplan-Meier survival curves. (A) Progression-free survival (PFS) for patients in the efficacy set (n=33). (B) Overall survival (OS) for patients in the efficacy set (n=33). (C) PFS comparison between p16+ oropharyngeal patients (n=12) and others (n=21). (D) OS comparison between p16+ oropharyngeal patients (n=12) and others (n=21). (E) PFS comparison between patients with *TP53* mutation (n=13) versus others (n=20). (F) OS

comparison between patients with *TP53* mutation (n=13) versus others (n=20). (G) PFS comparison based on canonical mutation and *TP53* mutation status. (H) OS comparison based on canonical mutation and *TP53* mutation status.